



FOR IMMEDIATE RELEASE

**March 15<sup>th</sup>, 2022**

**Anwita Biosciences, Inc. Announces Upcoming Late-Breaking Poster Presentation Supporting the Development of Mableukine-2PD1 at AACR 2022 Annual Meeting**

SAN CARLOS, California, March 15<sup>th</sup>, 2022 – Anwita Biosciences, Inc. (“Anwita”), a clinical-stage biopharmaceutical company developing proprietary optimized cytokine-based therapeutics for cancer patients, today announced the publication of a late-breaking presentation on Mableukine-2PD1 at the American Association of Cancer Research (AACR) Annual Meeting. Mableukine-2PD1, composed of an anti-PD-1 monoclonal antibody and a potency optimized no- $\alpha$  IL-2, is a highly safe and potent bifunctional fusion product capable of selectively expanding T cells within the tumor microenvironment without activating systemic toxicity. The meeting will take place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Details for the abstract and poster presentation are as follows:

<u>Abstract Number:</u>	LB218
<u>Title:</u>	A safe and highly potent anti-PD-1-IL-2c fusion that decouples efficacy and toxicity of IL-2 therapy
<u>Session Title:</u>	Late-Breaking Research Immunology 2
<u>Session Data and Time:</u>	Wednesday Apr 13, 2022, 9:00 AM - 12:30 PM
<u>Location:</u>	Exhibit Halls D-H, Poster Section 18

E-poster of the above abstract is expected to be released at 1:00 PM ET on Friday, April 8<sup>th</sup> per AACR guidance.

**About Anwita Biosciences, Inc.**

Anwita Biosciences, Inc. is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. Anwita specializes in the discovery and development of optimized immunotherapeutics, leveraging its core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering.

**Investor Relations**

Contact: Investor Relations

Telephone: (650) 600-9828

Email: [contact@anwitabio.com](mailto:contact@anwitabio.com)

Website: [www.anwitabio.com](http://www.anwitabio.com)